Erectile dysfunction and its relationship with cardiovascular risk factors and disease

Saudi Medical Journal

Volumn 30, Issue 2, 2009, Pages 184-190

  Irekpita, Eshiobo ^a   Salami, Taofik A ^a  

^a AMBROSE ALLI UNIVERSITY   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE V INHIBITOR; RAMIPRIL; TELMISARTAN;

ARTERY DIAMETER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; NEUROPATHY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PENIS ERECTION; REVIEW; RISK ASSESSMENT; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; VASCULAR ENDOTHELIUM; VASODILATATION;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; ERECTILE DYSFUNCTION; HUMANS; MALE; RISK FACTORS;

EID: 66649084416     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. National Institutes of Health Consensus Development Panel on Impotence. Proceedings of a conference held December 7-9, 1992; Bethesda (Maryland), USA. JAMA 1993; 270: 83-90.
2. Pommerville P. Erectile dysfunction: An overview. Can J Urol 2003; 10 (Suppl 1): 2-6.
3. El Sakka AI. Association of risk factors and medical comorbidities with male erectile dysfunctions. J Sex Med 2007; 4: 1691-1700.
4. Valequelte L. Historical review of erectile dysfunction. Can J Urol 2003; 10 (Supp 1): 7-11.
5. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction, Int J Impot Res 2003; 15: 63-71.
6. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL, Prevalence of erectile dysfunction: A systematic review of population based studies. Int J Impot Res 2002; 14: 422-432.
7. Shaeer KZ, Osegbe DN, Siddiqui SH, Razzaque A, Glasser DB, Jaguste V. Prevalence of erectile dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan, Egypt and Nigeria. Int J Impot Res 2003; 15 (Suppl 1): S8-S14.
8. Fowler CJ. The neurology of male sexual dysfunction and its investigation by clinical neurophysiological methods. Br J Urol 1998; 81; 785-795.
9. El-Sakka AI, Lue TF. Physiology of penile erection. Scientific World Journal 2004; 4 (Suppl 1); 128-134.
10. Sharlip ID. Diagnosing male erectile dysfunction, American Urological Association 95th Annual General Meeting. 2000 April 29-May 4; Atlanta, Georgia.
11. Gillenwater JY, Howards SS, Mitchell ME, Grayhack JT. Adult and Paediatric Urology. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 1956-1983.
12. Benson GS, McConnell J, Lipshultz LI, Corriere JN Jr, Wood J. Neuromorphology and neuropharmacology of the human penis: An in vitro study. J Clin Invest 1980; 65; 506-513.
13. John R, Brewster S, Biers S. Oxford Hand Book of Urology. New York (NY): Oxford University Press; 2006. p. 476.
14. Walsh PC, Donker PJ. Impotence following radical prostatectomy; Insight unto aetiology and prevention. J Urol 1987; 12: 694.
15. Benoit G, Delmas V, Gillot C, Jardin A. The anatomy of erection. Surg Radiol Anat 1987; 9: 263-272.
16. Davies MG, Fulton GJ, Hagen PO. Clinical biology of nitric oxide. Br J Surg 1995; 82; 1598-1610.
17. Mumtaz FH, Khan MA, Thompson CS, Morgan RJ, Mikhailidis DP. Nitric Oxide in the lower genito urinary tract: Physiological and Pharmacological Implications. Br J Urol 2000; 35; 567-578.
18. Montorsi F, Briganti A, Salonia A, Deho' F, Zanni G, Cestari A. et al. The aging male and erectile dysfunction. Br J Urol 2003; 92: 516-520.
19. Carrier S. Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol 2003; 10 (Suppl 1): 12-16.
20. Watts GF, Chew KK, Stuckey BG. The erectile-endothelial dysfunction nexus; new opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med 2007; 4; 263-273.
21. Frederick JS, Ramzi SC. Blood vessels. In: Ramzi SC, Vinay K, Tucker C, editors. Robins pathological basis of diseases. 6th ed. Philadelphia (PA): WB Saunders Company: 1999. p. 8-10.
22. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
23. Tsao PS, Wang B, Buitrago R, Shyy JY. Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 3: 934-940.
24. Noll G, Luscher TF. The endothelium in acute coronary syndromes. Eur Heart J 1998; 19: C30-c38.
25. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I. Nitric oxide-like factor mediates non adrenergic non cholinergic neurogenic relaxation of the penile corpus cavernous smooth muscle. J Clin Invest 1991; 88: 112-118.
26. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 2007; 15; 76-86.
27. Naoumova R, Scott J. The pathogenesis of atherosclerosis. In: Ledingham JGG, Warrell DA, editors. Concise Oxford Textbook of Medicine. United Kingdom (UK): Oxford University Press; 2000. p. 54-504.
28. Burnett AL. The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens (Greenwich) 2006; 8 (Suppl 4): S53-S62.
29. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 155-126.
30. Watts GF, Chew KK, Stuckey BGA. The erectile-endothelial dysfunction nexus: New opportunities for cardiovascular risk prevention. Nat Clin Pract Cardiovasc Med 2007; 4: 263-273.
31. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007; 61: 2019-2025.
32. Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ, et al. Erectile dysfunction and statins treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141-145.
33. Sun P, Cameroon A, Seftel A, Shabsigh R, Niederberger C, Guay A. Erectile dysfunction. An Observable marker of diabetes mellitus? A large national epidemiology study. J Urol 2006; 176: 1081-1085.
34. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1454-1486.
35. Fasanmade OA, Okubadejo NU. Magnitude and gender distribution of obesity and abdominal adiposity in Nigerians with type 2 diabetes mellitus. Niger J Clin Practice 2007; 10: 52-57.
36. Meng X, Li ZM, Zhou YJ, Cao YL, Zhang J. Effect of the anti-oxidant alpha lipolic acid on aptoptosis in human umbilical vein endothelial cells induced by high glucose. Clin Exp Med 2008; 8: 43-49.
37. Di Filippo C, Verza M, Coppola L, Rossi F, D'Amico M, Marfella R. Insulin resistance and postprandial hyperglycemia the bad companions in natural history of diabetes: Effects on health of vascular tree. Curr Diabetes Review 2007; 3: 268-273.
38. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
39. Ayodele OE, Alebiosu CO, Salako BL, Awoden OG, Abigun AD. Target organ damage and associated clinical conditions among Nigerians with treated hypertension. Cardiovasc J S Afr 2005: 16: 89-93.
40. Essien OE, Peters EJ, Udoh AE, Ekott JU, Odigwe CO. Prevalence and pattern of abnormal glucose tolerance in adult Nigerians with primary hypertension. Niger J Med 2007; 16: 50-56.
41. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res 2007; 19: 296-302.
42. Buranakitjaroen P, Phoojaroenchanachai M, Saravich S. Prevalence of erectile dysfunction among treated hypertensive males. J Med Assoc Thai 2006; 89 (Suppl 5): S28-S36.
43. Modebe O. Erectile failure among medical clinical patients. Afr J Med Sci 1990; 19: 259-264.
44. Shiri R, Koskimäki J, Häkkinen J, Auvinen A, Tammela TL, Hakama M. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007; 19: 208-212.
45. Böhm M, Baumhäkel M, Probstfield JL, Schmieder R, Yusuf S, Zhao F, et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007; 154: 94-101.
46. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM, Links nitric oxide protects againts leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1652-1659.
47. Peter LW, James HFR. Atherosclerotic BIology and Epidemiology of Diease. In: Topol EJ, Califf RM, Isner J, Prystowsky EN, Swain J, editors. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 1-20.
48. Opadijo OG, Akande AA, Jimoh AK. Prevalence of coronary heart disease risk factors in Nigerians with systemic hypertension. Afr J Med Med Sci 2004; 33: 121-125.
49. Ukoh VA, Okorofuo IA. Plasma lipid profile in Nigerians with normal blood pressure, hypertension and other acquired cardiac conditions. East Afr Med J 2007; 84: 267-270.
50. Schwarz ER, Rodriguez J. Sex and the heart. Int J Impot Res 2005; 17 (Suppl 1): S4-S6.
51. Rastogi S, Rodriguez JJ, Kapur V, Schwarz ER. Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach the problem. Int J Impot Res 2005; 17 (Suppl 1): S25-S36.
52. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N. Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006; 48: 1111-1119.
53. Ness AR, Smith GD. The epidemiology of ischaemic heart disease. In: Warrell DA, Cox TM, Firth JD, Edward J, Benz MD, editors. Oxford Textbook of Medicine. 4th ed. Oxford (UK): Oxford University Press; 2003. p. 315-607.
54. Alkhayal S, Lehmann V, Thomas P. A simple non invasive test to detect vascular disease in patients with erectile dysfunction: A novel menthod. J Sex Med 2006; 3: 331-336.
55. Basal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005; 2: 96-103.
56. Guay A, Jacobson J. The relationship between testosterone levels the metabolic syndrome (by two criteria) and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 2007; 4: 1046-1055.
57. Harin P, Shabsigh R. Sildenafil citrate (Viagra) (R): A review. Am J Urol 1999; 18: 274-279.
58. Herschorn S. Cardiovascular safety of PDE5 inhibitors. Can J Urol 2003; 10 (Suppl 1): S23-S28.
59. Parker JD, Bart BA, Webb DJ, Koren MJ, Siegel RL, Wang H, et al. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med 2007; 35: 1863-1868.
60. Webb DJ, Freestone S, Allen MJ, Muirhead GJ, Sildenafil citrate and blood-pressure-lowering drugs: Result of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: C21-C28.
61. Velásquez López JG, Agudelo Restrepo CA, Yepes Gómez D, Uribe Trujillo CA. [Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. Actas Urol Esp 2007; 31: 52-57. Spanish.
62. Tikkanen MJ, Jackson G, Tammela T, Assmann G, Palomäki A. Kupari M, et al. Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract 2007; 61: 265-268.
63. Roumeguère T, Wespes E. [Erectile dysfunction and cardiovascular disease in clinical practice]. Rev Med Brux 2007; 28: 360-366. French.